Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice

Journal of the American Society of Nephrology

Volumn 10, Issue 7, 1999, Pages 1430-1439

  Gross, Volkmar ^b   Schneider, Wolfgang ^b   Schunck, Wolf Hagen ^b   Mervaala, Eero ^b   Luft, Friedrich C ^a  

^a FRANZ VOLHARD CLINIC   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; DEOXYCORTICOSTERONE ACETATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR SPACE; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY PERFUSION; KIDNEY VASCULAR RESISTANCE; LASER DOPPLER FLOWMETRY; MOUSE; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL;

EID: 0033033705     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Luft FC: Treatment and prevention of hypertension: Where have we been and were are we going? Kidney Int 48[Suppl 50]: S14-S18, 1995
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: For the west Scotland coronary prevention study group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307, 1995
3. Pedersen TR: For the Scandinavian simvastatin survival study group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 344: 1383-1389, 1994
4. Treasure HB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487, 1995
5. Goa KL, Barradell LB, Plosker GL: Bezafibrate: An update of its pharmacology and use in the management of dyslipidemia. Drugs 52: 725-753, 1996
6. Roullet JB, Xue H, Pappu AS, Roulet C, Holcomb S, McCarron DA: Mevalonate availability and cardiovascular function. Proc Natl Acad Sci USA 90: 11728-11732, 1993
7. Roullet JB, Xue H, Roullet CM, Fletcher WS, Cipolla MJ, Harker CT, McCarron DA: Mevalonat availability affects human and rat resistant vessel function. J Clin Invest 96: 239-244, 1995
8. Roullet JB, Xue H, Chapman J, McDougal P, Roulett CM, McCarron DA: Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 97: 2384-2390, 1996
9. Jiang J, Roman RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 30: 968-974, 1997
10. Roman RJ, Ma YH, Frohlich B, Markham B: Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 21: 985-988, 1993
11. Gross V, Lippoldt A, Bohlender J, Bader M, Hansson A, Luft FC: Cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. J Am Soc Nephrol 9: 346-354, 1998
12. Krege JH, Hodgin JB, Hagaman JR, Smithies O: A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995
13. Gross V, Lippoldt A, Luft FC: Pressure diuresis and natriuresis in DOCA-salt mice. Kidney Int 52: 1364-1368, 1997
14. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC: Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 156: 249-252, 1996
15. Hafez KS, Inman SR, Stowe NT, Novick AC: Renal hemodynamic effects of lovastatin in a renal ablation model. Urology 48: 862-867, 1996
16. Mattson DL, Lu S, Roman RJ, Cowley AW Jr: Relationship between renal perfusion pressure and blood flow in different regions of the kidney. Am J Physiol 264: R578-R583, 1993
17. Cowley AW Jr, Mattson DL, Lu S, Roman RJ: The renal medulla and hypertension. Hypertension 25: 663-673, 1995
18. Lu S, Mattson DL, Cowley AW Jr: Renal medullary captopril delivery lowers blood pressure in spontaneously hypertensive rats. Hypertension 23: 337-345, 1994
19. Nakanishi K, Mattson DL, Cowley AW Jr: Role of renal medullary blood flow in the development of L-NAME hypertension in rats. Am J Physiol 268: R317-R323, 1995
20. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20: 651-658, 1992
21. Endo A, Tsujita Y, Kuroda M, Tanzawa K: Effects of ML-236B on cholesterol metabolism in mice and rat: Lack of hypocholesterolemic activity in normal animals. Biochem Biophys Acta 575: 266-276, 1979
22. Amin P, Rutledge RZ, Needle SJ, Hele DJ, Neuenswander K, Bush RC, Bilder GE, Perrone MH: RPR 101821, a new potent cholesterol-lowering agent: Inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol 353: 233-240, 1996
23. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 348: 1079-1082, 1996
24. Massy ZA, Keane WF, Kasiske BL: Inhibition of mevalonat pathway: Benefits beyond cholesterol reduction? Lancet 347: 102-103, 1996
25. Lippoldt A, Gross V, Schneider K, Hannson A, Nadaud S, Schneider W, Bader M, Yagil C, Yagil Y, Luft FC: NO synthetase and renin angiotensin system gene expression in salt-sensitive and salt-resistant Sabra rats. Hypertension 30: 409-415, 1997
26. Hirata Y, Hayakawa H, Kakogi M, Tojo A, Suzuki E, Kimura K, Goto A, Kikuchi K, Nagano T, Hirobe N, Omata M: Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 27: 672-678, 1996
27. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, Omata M: Direct measurement of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteralion in salt-induced hypertension. Circulation 91: 1229-1235, 1995
28. Chin SY, Wang CT, Majid DAS, Navar LG: Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. Am J Physiol 274: F876-F882, 1998
29. Mattson DL, Roman RJ, Cowley AW Jr: Role of nitric oxide in renal papillary blood flow and sodium excretion. Hypertension 19: 766-769, 1992
30. Laufs U, Fata LV, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135, 1998
31. Guarasci GR, Kline RL: Pressure natriuresis following acute and chronic inhibition of nitric oxide synthase in rats. Am J Physiol 270: R469-R478, 1996
32. Agrawal B, Kopecky J, Kränzlin B, Rohmeiss P, Pill J, Gretz N: Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats. Nephrol Dial Transplant 13: 333-339, 1998
33. Johnson EF, Palmer CNA, Griffin KJ, Hsu MH: Role of peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J 10: 1241-1248, 1996
34. Simpson AECM: The cytochrome P 450 4 (CYP4) family. Gen Pharmacol 28: 351-359, 1997
35. Rahman M, Wright JT Jr, Douglas JG: The role of cytochrome P450-dependent metabolites of arachidonic acid in blood pressure regulation and renal function: A review. Am J Hypertens 10: 356-365, 1997
36. Macita K, Falck JR, Capdevila JH: Cytochrome P450, the arachidonic acid cascade, and hypertension: New vistas for an old enzyme. FASEB J 10: 1456-1463, 1996
37. Roman RJ, Alonso-Galicia M, Wilson TW: Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Am J Hypertens 10: 63S-67S, 1997
38. Omata K, Abraham NG, Schwartzman ML: Renal cytochrome P450-dependent arachidonic acid metabolism: Intrarenal localization and hormonal regulation in spontaneously hypertensive rats. Am J Physiol 262: F591-F599, 1992
39. Escalanta B, Sacerdoti D, Davidian MM, Laniado-Schwartzman MC, McGiff JC: Chronic treatment with tin normalized pressure in spontaneously hypertensive rats. Hypertension 17: 776-779, 1991
40. Franchini KG: Hemodilution mediates changes in renal hemodynamics after acute volume expansion in rats. Am J Physiol 274: R1670-R1676, 1998
41. Stegmeier K, Stork H, Lenz H, Leuschner F, Liede V: Pharmacology and mode of action of bezafibrate in animals. In: Lipoproteins and Coronary Heart Disease, edited by Greten H, Lang PD, Schettler G, New York, Baden-Baden, Cologne, Gerhardt Witzstock Publishing House, 1980, pp 76-82